Production (Stage)
Inhibitor Therapeutics, Inc.
INTI
$0.054
$0.0048.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 438.50K | 596.50K | 493.60K | 345.40K | 514.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 674.60K | 1.48M | 813.20K | 585.10K | 774.80K |
| Operating Income | -674.60K | -1.48M | -813.20K | -585.10K | -774.80K |
| Income Before Tax | -632.80K | -1.42M | -731.00K | -501.70K | -684.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -632.80K | -1.42M | -731.00K | -501.70K | -684.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -632.80K | -1.42M | -731.00K | -501.70K | -684.70K |
| EBIT | -674.60K | -1.48M | -813.20K | -585.10K | -774.80K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 172.32M | 172.32M | 172.32M | 172.32M | 172.08M |
| Average Diluted Shares Outstanding | 172.32M | 172.32M | 172.32M | 172.32M | 172.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |